Grifols' AMBAR Phase 3 clinical trial was designed to assess the effect of plasma replacement therapy in Alzheimer's disease (AD), delivered via intravenous infusions. The results of this trial, which were published in Alzheimer's and Dementia in 2020, showed that the AMBAR procedure could slow cognitive decline in people with mild or moderate AD.
Following on from the completion of the AMBAR clinical trial, which recruited almost 500 participants via 41 different treatment centres in Spain and the US, Grifols has announced the opening of an AMBAR centre in Barcelona, in collaboration with Fundació Acé. The new AMBAR centre will be managed by Fundació Acé, and is located at its medical centre in Barcelona. It is hoped that the Barcelona AMBAR centre, alongside others in the EU, US and China, will generate further medical data to help optimise the development of the AMBAR procedure.
